[英夫利昔单抗治疗克罗恩病——实用指南：奥地利胃肠病学和肝病学会慢性炎症性肠病工作组的最新共识]
[Infliximab therapy for Crohn's disease - a practical guideline: actualised consensus of the working group for chronic inflammatory bowel diseases of the Austrian Society for Gastroenterology and Hepatology].
作者信息
Reinisch W, Dejaco C, Feichtenschlager T, Haas T, Kaser A, Miehsler W, Novacek G, Petritsch W, Platzer R, Tilg H, Vogelsang H, Knoflach P
机构信息
AKH Wien, Univ.-Klinik für Innere Medizin III, Klin. Abteilung f. Gastroenterologie und Hepatologie, Wien, Österreich.
出版信息
Z Gastroenterol. 2011 Apr;49(4):534-42. doi: 10.1055/s-0029-1245930. Epub 2011 Mar 25.
Infliximab is a monoclonal antibody against tumor necrosis factor alpha (TNF-α), which is approved for the treatment of chronic inflammatory bowel disease (IBD) such as Crohn's disease (CD), fistulating Crohn's disease (FCD), ulcerative colitis (UC), and paediatric ulcerative colitis (PUC) from 6 years onwards. Besides its therapeutic efficacy, this antibody therapy is characterised by its side effects profile, which has been addressed in a seperate consensus statement by the Working Group for chronic inflammatory bowel diseases within the Austrian Society for Gastroenterology and Hepatology. Infliximab is an effective treatment option for the above-mentioned indications; however, use of this agent requires special knowledge to assess the benefit-risk profile for each patient individually.
英夫利昔单抗是一种抗肿瘤坏死因子α（TNF-α）的单克隆抗体，已被批准用于治疗慢性炎症性肠病（IBD），如克罗恩病（CD）、瘘管性克罗恩病（FCD）、溃疡性结肠炎（UC）以及6岁及以上儿童的溃疡性结肠炎（PUC）。除了其治疗效果外，这种抗体疗法还具有其副作用特征，奥地利胃肠病学和肝病学会慢性炎症性肠病工作组已在一份单独的共识声明中对此进行了阐述。英夫利昔单抗是上述适应症的一种有效治疗选择；然而，使用这种药物需要专业知识，以便为每个患者单独评估其效益风险情况。
Zotero 插件